Figure 4From: Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to MatuzumabCombination of matuzumab with PD98059, a MAPK inhibitor, induces antagonistic effects in A431, Caski and C33A cells. (A) Effects of combined treatment of matuzumab (100 μg/mL) with a MAPK pathway inhibitor, PD98059 (25 μM), on cell viability by MTT assay and (B) Western blotting analysis of phosphorylation of p44/42 (ERK) 1/2 on Caski and C33A cells.Back to article page